Inflammation, Chronic Disease, and Cancer: Is Psychological Distress the Common Thread?

  • Feridey N. Carr
  • Elizabeth M. Sosa


Mounting evidence suggests that the inflammatory mechanism plays a central role in the development and exacerbation of multiple chronic illnesses, including gastrointestinal, pulmonary, and cardiovascular disease, as well as obesity and rheumatoid arthritis. It has further been suggested that chronic inflammation is correlated with various types of cancer. While multiple studies have demonstrated that certain chronic diseases predict increased risk of malignancies, recent scholarship suggests that the inflammatory mechanism may in fact serve as a major factor in the pathogenesis of cancer. As psychological stress is known to influence individual levels of pro-inflammatory cytokines, it is possible that mental health problems such as chronic stress and depression may indirectly contribute to cancer development.


Chronic Obstructive Pulmonary Disease Systemic Lupus Erythematosus Inflammatory Bowel Disease Ulcerative Colitis Psychological Distress 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.PubMedGoogle Scholar
  2. 2.
    Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004;14:433–9.PubMedGoogle Scholar
  3. 3.
    Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121(11):2373–80.PubMedGoogle Scholar
  4. 4.
    Rakoff-Nahoum S. Why cancer and inflammation? Yale J Biol Med. 2006;79(3–4):123–30.PubMedGoogle Scholar
  5. 5.
    Gulumian M. The role of oxidative stress in diseases caused by mineral dusts and fibres: current status and future of prophylaxis and treatment. Mol Cell Biochem. 1999;196:69–77.PubMedGoogle Scholar
  6. 6.
    Ekbom A, Helmick C, Zack M, Adami H-O. Ulcerative colitis and colorectal cancer. N Engl J Med. 1990;323:1228–33.PubMedGoogle Scholar
  7. 7.
    Mantovani A, Paola A, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.PubMedGoogle Scholar
  8. 8.
    Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650–9.PubMedGoogle Scholar
  9. 9.
    Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431–6.PubMedGoogle Scholar
  10. 10.
    Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7: 41–51.PubMedGoogle Scholar
  11. 11.
    Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A. 2003;100:2645–50.PubMedGoogle Scholar
  12. 12.
    Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442:461–5.PubMedGoogle Scholar
  13. 13.
    Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3(9):745–56.PubMedGoogle Scholar
  14. 14.
    Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 2002;13(2): 135–41.PubMedGoogle Scholar
  15. 15.
    Ariztia EV, Lee CJ, Gogoi R, Fishman DA. The tumor microenvironment: key to early detection. Crit Rev Clin Lab Sci. 2006;43:393–425.PubMedGoogle Scholar
  16. 16.
    Negaard HF, Iversen N, Bowitz-Lothe IM, et al. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia. 2009;23(1):162–9.PubMedGoogle Scholar
  17. 17.
    Kulbe H, Levinson NR, Balkwill F, Wilson JL. The chemokine network in cancer—much more than directing cell movement. Int J Dev Biol. 2004;48(5–6):489–96.PubMedGoogle Scholar
  18. 18.
    Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today. 1992;13:265–70.PubMedGoogle Scholar
  19. 19.
    Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biocehem Pharmacol. 2006;72:1605–21.Google Scholar
  20. 20.
    Dantzer R, O’Connor J, Freund G, Johnson R, Kelley K. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46–57.PubMedGoogle Scholar
  21. 21.
    Quan N, Banks WA. Brain-immune communication pathways. Brain Behav Immun. 2007;21(6):727–35.PubMedGoogle Scholar
  22. 22.
    Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349(9063): 1436–42.PubMedGoogle Scholar
  23. 23.
    Steptoe A, Hamer M, Chida Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav Immun. 2007;21(7):901–12.PubMedGoogle Scholar
  24. 24.
    Leonard BE. The concept of depression as a dysfunction of the immune system. Curr Immunol Rev. 2010;6(3):205–12.PubMedGoogle Scholar
  25. 25.
    Godbout JP, Berg BM, Krzyszton C, Johnson RW. Alpha-tocopherol attenuates NFkappaB activation and pro-inflammatory cytokine production in brain and improves recovery from lipopolysaccharide-induced sickness behavior. J Neuroimmunol. 2005;169(1–2):97–105.PubMedGoogle Scholar
  26. 26.
    Heyen JR, Ye S, Finck BN, Johnson RW. Interleukin (IL)-10 inhibits IL-6 production in microglia by preventing activation of NF-kappaB. Brain Res Mol Brain Res. 2000;77(1):138–47.PubMedGoogle Scholar
  27. 27.
    Stewart JC, Rand KL, Muldoon MF, Kamarck TW. A prospective evaluation of the directionality of the depression-inflammation relationship. Brain Behav Immun. 2009;23(7):936–44.PubMedGoogle Scholar
  28. 28.
    Brown KD, Claudio E, Siebenlist U. The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther. 2008; 10(4):212.PubMedGoogle Scholar
  29. 29.
    Amos N, Lauder S, Evans A, Feldmann M, Bondeson J. Adenoviral gene transfer into osteoarthritis synovial cells using the endogenous inhibitor Ikappa B alpha reveals that most, but not all, inflammatory and destructive mediators are NF-kappa B dependent. Rheumatology. 2006;45:1201–9.PubMedGoogle Scholar
  30. 30.
    Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis. 2000;59:121–7.Google Scholar
  31. 31.
    Guerne PA, Zuraw BL, Vaughan JH, Carson DA, Lotz M. Synovium as a source of interleukin 6 in vitro: contribution to local and systemic manifestations of arthritis. J Clin Invest. 1989;83:585–92.PubMedGoogle Scholar
  32. 32.
    Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52:232–4.PubMedGoogle Scholar
  33. 33.
    Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. Br Med J. 1998;317:180–1.Google Scholar
  34. 34.
    Baeklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692–701.Google Scholar
  35. 35.
    Jones M, Symmons D, Finn J, et al. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol. 1996;35:738–45.PubMedGoogle Scholar
  36. 36.
    Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol. 1999;26:1705–14.PubMedGoogle Scholar
  37. 37.
    van de Rijn M, Cleary M, Variakojis D, et al. Epstein-Barr virus clonality in lymphomas occurring in patients with rheumatoid arthritis. Arthritis Rheum. 1996;39:638–42.PubMedGoogle Scholar
  38. 38.
    Dawson T, Starkbaum G, Wood B, et al. Epstein-Barr virus, methotrexate, and lymphoma in patients with rheumatoid arthritis and primary Sjogren’s syndrome: case series. J Rheumatol. 2001;28:47–53.PubMedGoogle Scholar
  39. 39.
    Wolfe F. Inflammatory activity, but not methotrexate or prednisone use predicts non-Hodgkins lymphoma in rheumatoid arthritis: a 25-year study of 1,767 RA patients. Arthritis Rheum. 1998;41:S188.Google Scholar
  40. 40.
    Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(2):R45.PubMedGoogle Scholar
  41. 41.
    Bachen EA, Chesney MA, Criswell LA. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum. 2009; 61(6):822–9.PubMedGoogle Scholar
  42. 42.
    Seguí J, Ramos-Casals M, García-Carrasco M, et al. Psychiatric and psychosocial disorders in patients with systemic lupus erythematosus: a longitudinal study of active and inactive stages of the disease. Lupus. 2000;9(8):584–8.PubMedGoogle Scholar
  43. 43.
    Waterloo K, Omdal R, Husby G, Mellgren SI. Emotional status in systemic lupus erythematosus. Scand J Rheumatol. 1998;27(6):410–4.PubMedGoogle Scholar
  44. 44.
    Nery FG, Borba EF, Viana VS, et al. Prevalence of depressive and anxiety disorders in systemic lupus erythematosus and their association with anti-ribosomal P antibodies. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(3):695–700.PubMedGoogle Scholar
  45. 45.
    Mella LF, Bértolo MB, Dalgalarrondo P. Depressive symptoms in rheumatoid arthritis. Rev Bras Psiquiatr. 2010;32(3):257–63.PubMedGoogle Scholar
  46. 46.
    Davis MC, Zautra AJ, Younger J, Motivala SJ, Attrep J, Irwin MR. Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue. Brain Behav Immun. 2008;22(1):24–32.PubMedGoogle Scholar
  47. 47.
    Carney RM, Freedland KE, Miller GE, Jaffe AS. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J Psychosom Res. 2002;53(4):897–902.PubMedGoogle Scholar
  48. 48.
    Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24–31.PubMedGoogle Scholar
  49. 49.
    Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA. Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol. 2002;90(12):1279–83.PubMedGoogle Scholar
  50. 50.
    Miller GE, Freedland KE, Carney RM, Stetler CA, Banks WA. Pathways linking depression, adiposity, and inflammatory markers in healthy young adults. Brain Behav Immun. 2003;17(4):276–85.PubMedGoogle Scholar
  51. 51.
    Low CA, Cunningham AL, Kao AH, Krishnaswami S, Kuller LH, Wasko MC. Association between C-reactive protein and depressive symptoms in women with rheumatoid arthritis. Biol Psychol. 2009;81(2): 131–4.PubMedGoogle Scholar
  52. 52.
    Carr, FN, Nicassio, PM, Ishimori, ML, Moldovan, I, Katsaros, E, Torralba, K. Depression predicts patient-reported fatigue in systemic lupus erythematosus (SLE). In: Society for Behavioral Medicine Annual Meeting. Washington, DC; April 2011.Google Scholar
  53. 53.
    Bruce TO. Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. Curr Psychiatry Rep. 2008;10(3):258–64.PubMedGoogle Scholar
  54. 54.
    Kiebles JL, Doerfler B, Keefer L. Preliminary evidence supporting a framework of psychological adjustment to inflammatory bowel disease. Inflamm Bowel Dis. 2010;16(10):1685–95.PubMedGoogle Scholar
  55. 55.
    Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126(2): 451–9.PubMedGoogle Scholar
  56. 56.
    Itzkowitz SH, Yio X. Inflammation and Cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287(1):G7–17.PubMedGoogle Scholar
  57. 57.
    Mitsuyama K, Matsumoto S, Rose-John S, et al. STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut. 2006;55:1263–9.PubMedGoogle Scholar
  58. 58.
    Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity. 2004;21:491–501.PubMedGoogle Scholar
  59. 59.
    Braegger CP, Nicholls S, Murch SH, Steohens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992;339(8785):89–91.PubMedGoogle Scholar
  60. 60.
    Theiss AL, Jenkins AK, Okoro NI, Klapproth JMA, Merlin D, Sitaraman SV. Prohibitin inhibits tumor necrosis factor alpha-induced nuclear factor-kappa b nuclear translocation via the novel mechanism of decreasing importin-α3 expression. Mol Biol Cell. 2009;20(20):4412–23.PubMedGoogle Scholar
  61. 61.
    Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, et al. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor NFKB1, and peroxisome proliferator-activated receptor with colorectal cancer. Cancer Res. 2003;63(13):3560–6.PubMedGoogle Scholar
  62. 62.
    Jayaram H, Satsangi J, Chapman RW. Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: fact or fiction? Gut. 2001;48:430–4.PubMedGoogle Scholar
  63. 63.
    Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol. 1999;94(6):1643–9.PubMedGoogle Scholar
  64. 64.
    Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol. 1997;39:1–20.PubMedGoogle Scholar
  65. 65.
    Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer. 2003;276:276–85.Google Scholar
  66. 66.
    Farrokhyar F, Marshall JK, Easterbrook B, Irvine EJ. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis. 2006;12(1):38–46.PubMedGoogle Scholar
  67. 67.
    Kovács Z, Kovács F. Depressive and anxiety symptoms, dysfunctional attitudes and social aspects in irritable bowel syndrome and inflammatory bowel disease. Int J Psychiatry Med. 2007;37(3):245–55.PubMedGoogle Scholar
  68. 68.
    Maunder RG, Levenstein S. The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence. Curr Mol Med. 2008;8(4):247–52.PubMedGoogle Scholar
  69. 69.
    Cámara RJ, Schoepfer AM, Pittet V, Begré S, von Känel R; the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) Group. Mood and nonmood components of perceived stress and exacerbation of crohn’s disease. Inflamm Bowel Dis. 2011. doi: 10.1002/ibd.21623.
  70. 70.
    Raison CL, Lowry CA, Rook GA. Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. Arch Gen Psychiatry. 2010;67(12):1211–24.PubMedGoogle Scholar
  71. 71.
    Rao AV, Bested AC, Beaulne TM, et al. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog. 2009;1(1):6.PubMedGoogle Scholar
  72. 72.
    Rini C, Jandorf L, Valdimarsdottir H, Brown K, Itzkowitz SH. Distress among inflammatory bowel disease patients at high risk for colorectal cancer: a preliminary investigation of the effects of family history of cancer, disease duration, and perceived social support. Psychooncology. 2008;17(4):354–62.PubMedGoogle Scholar
  73. 73.
    Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002;288:1723–7.PubMedGoogle Scholar
  74. 74.
    Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–16.PubMedGoogle Scholar
  75. 75.
    Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070–7.PubMedGoogle Scholar
  76. 76.
    Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132(6):2169–80.PubMedGoogle Scholar
  77. 77.
    Festa A, D’Agostino Jr R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation. 2000;102:42–7.PubMedGoogle Scholar
  78. 78.
    Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41:1241–8.PubMedGoogle Scholar
  79. 79.
    Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280:E745–51.PubMedGoogle Scholar
  80. 80.
    Rajala MW, Sherer PE. Minireview: the adipocyte—at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology. 2003;144:3765–73.PubMedGoogle Scholar
  81. 81.
    Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145:2273–82.PubMedGoogle Scholar
  82. 82.
    Bilan PJ, Samokhvalov V, Koshkina A, Schertzer JD, Samaan MC, Klip A. Direct and macrophage-mediated actions of fatty acids causing insulin resistance in muscle cells. Arch Physiol Biochem. 2009;115: 176–90.PubMedGoogle Scholar
  83. 83.
    Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–7.PubMedGoogle Scholar
  84. 84.
    Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95:2409–15.PubMedGoogle Scholar
  85. 85.
    Fernandez-Real JM, Pickup JC. Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2008;19:10–6.PubMedGoogle Scholar
  86. 86.
    Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C. The implication of obesity and central fat on markers of chronic inflammation: the attica study. Artherosclerosis. 2005;183:308–15.Google Scholar
  87. 87.
    Solinas G, Naugler W, Galimi F, Lee MS, Karin M. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc Natl Acad Sci U S A. 2006;103:16454–9.PubMedGoogle Scholar
  88. 88.
    Lamb RE, Goldstein BJ. Modulating an oxidative-inflammatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function. Int J Clin Pract. 2008;62:1087–95.PubMedGoogle Scholar
  89. 89.
    West IC. Radicals and oxidative stress in diabetes. Diabet Med. 2000;17:171–80.PubMedGoogle Scholar
  90. 90.
    Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106:2067–72.PubMedGoogle Scholar
  91. 91.
    Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23:599–622.PubMedGoogle Scholar
  92. 92.
    Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002;3:565–74.PubMedGoogle Scholar
  93. 93.
    Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–91.PubMedGoogle Scholar
  94. 94.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.PubMedGoogle Scholar
  95. 95.
    Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140(2):197–208.PubMedGoogle Scholar
  96. 96.
    de Wit LM, van Straten A, van Herten M, Penninx BW, Cuijpers P. Depression and body mass index, a u-shaped association. BMC Public Health. 2009;9:14.PubMedGoogle Scholar
  97. 97.
    Faith MS, Matz PE, Jorge MA. Obesity-depression associations in the population. J Psychosom Res. 2002;53(4):935–42.PubMedGoogle Scholar
  98. 98.
    Scott KM, McGee MA, Wells JE, Oakley Browne MA. Obesity and mental disorders in the adult general population. J Psychosom Res. 2008;64(1):97–105.PubMedGoogle Scholar
  99. 99.
    Penninx BW, Beekman AT, Honig A, et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry. 2001;58(3):221–7.PubMedGoogle Scholar
  100. 100.
    Keddie AM. Associations between severe obesity and depression: results from the National Health and Nutrition Examination Survey, 2005–2006. Prev Chronic Dis. 2011;8(3). Accessed 10 May 2011.
  101. 101.
    Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220–9.PubMedGoogle Scholar
  102. 102.
    Taylor VH, MacQueen GM. The role of adipokines in understanding the associations between obesity and depression. J Obes. 2010. doi: 10.1155/2010/748048
  103. 103.
    Talley NJ. Definitions, epidemiology, and impact of chronic constipation. Rev Gastroenterol Disord. 2004;4 Suppl 2:S3–10.PubMedGoogle Scholar
  104. 104.
    John BJ, Abulafi AM, Poullis A, Mendall MA. Chronic subclinical bowel inflammation may explain increased risk of colorectal cancer in obese people. Gut. 2007;56(7):1034–5.PubMedGoogle Scholar
  105. 105.
    Barbu C, Iordache M, Man MG. Inflammation in COPD: pathogenesis, local and systemic effects. Rom J Morphol Embryol. 2011;52(1):21–7.PubMedGoogle Scholar
  106. 106.
    Schunemann HJ, Dorn J, Grant BJ, et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000;118:656–64.PubMedGoogle Scholar
  107. 107.
    Bang KM, Gergen PJ, Kramer R, et al. The effect of pulmonary impairment on all-cause mortality in a national cohort. Chest. 1993;103:536–40.PubMedGoogle Scholar
  108. 108.
    Engstrom G, Lind P, Hedblad B, et al. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation. 2002;106(20):2555–60.PubMedGoogle Scholar
  109. 109.
    Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–26.PubMedGoogle Scholar
  110. 110.
    Hashimoto H, Kitagawa K, Hougaku H, et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation. 2001;104(1):63–7.PubMedGoogle Scholar
  111. 111.
    Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99:237–42.PubMedGoogle Scholar
  112. 112.
    Sin DD, Man SF. Systemic inflammation and mortality in chronic obstructive pulmonary disease. Can J Physiol Pharmacol. 2007;85:141–7.PubMedGoogle Scholar
  113. 113.
    Mannino DM. Epidemiology and global impact of chronic obstructive pulmonary disease. Semin Respir Crit Care Med. 2005;26:204–10.PubMedGoogle Scholar
  114. 114.
    Punturieri A, Szabo E, Croxton TL, Shapiro SD, Dubinett SM. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst. 2009;101:554–9.PubMedGoogle Scholar
  115. 115.
    Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645–53.PubMedGoogle Scholar
  116. 116.
    Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004;364:709–21.PubMedGoogle Scholar
  117. 117.
    O’Donnell RA, Richter A, Ward J, et al. Expression of ErbB receptors and mucins in the airways of long-term current smokers. Thorax. 2004;59:1032–40.PubMedGoogle Scholar
  118. 118.
    Kurie JM, Shin HJ, Lee JS, et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res. 1996;2: 1787–93.PubMedGoogle Scholar
  119. 119.
    Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn Jr PA. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol. 2002;29:3–14.PubMedGoogle Scholar
  120. 120.
    Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol. 2009;1(5):a000141.PubMedGoogle Scholar
  121. 121.
    Hayashi Y, Senjyu H, Iguchi A, et al. Prevalence of depressive symptoms in Japanese male patients with chronic obstructive pulmonary disease. Psychiatry Clin Neurosci. 2011;65(1):82–8.PubMedGoogle Scholar
  122. 122.
    Al-shair K, Kolsum U, Dockry R, Morris J, Singh D, Vestbo J. Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD. Respir Res. 2011;12:3.PubMedGoogle Scholar
  123. 123.
    Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5): 1165–85.PubMedGoogle Scholar
  124. 124.
    Al-Herz A, Ensworth S, Shojania K, Esdaile JM. Cardiovascular risk factor screening in systemic lupus erythematosus. J Rheumatol. 2003;30(3): 493–6.PubMedGoogle Scholar
  125. 125.
    Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus. 2000;9(3):170–5.PubMedGoogle Scholar
  126. 126.
    Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144(6):2195–200.PubMedGoogle Scholar
  127. 127.
    Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005;19(2):149–54.PubMedGoogle Scholar
  128. 128.
    Vázquez-Oliva G, Fernández-Real JM, Zamora A, Vilaseca M, Badimón L. Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects. J Hum Hypertens. 2005;19(6): 457–62.PubMedGoogle Scholar
  129. 129.
    Frasure-Smith N, Lespérance F, Irwin MR, Talajic M, Pollock BG. The relationships among heart rate variability, inflammatory markers and depression in coronary heart disease patients. Brain Behav Immun. 2009;23(8):1140–7.PubMedGoogle Scholar
  130. 130.
    Dyer AR, Stamler J, Berkson DM, Lindberg HA, Stevens E. High blood-pressure: a risk factor for cancer mortality? Lancet. 1975;1:1051–6.PubMedGoogle Scholar
  131. 131.
    Raynor Jr WR, Shekelle RB, Rossof AH, Maliza C, Paul O. High blood pressure and 17-year cancer mortality in the Western Electric Health Study. Am J Epidemiol. 1981;113:371–7.PubMedGoogle Scholar
  132. 132.
    Buck C, Donner A. Cancer incidence in hypertensives. Cancer. 1987;59:1386–90.PubMedGoogle Scholar
  133. 133.
    Chow WH, Gridley G, Fraumeni JF, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343:1305–11.PubMedGoogle Scholar
  134. 134.
    Grossman E, Messerli FH, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med. 2002;112:479–86.PubMedGoogle Scholar
  135. 135.
    Ohira T. Psychological distress and cardiovascular disease: the Circulatory Risk in Communities Study (CIRCS). J Epidemiol. 2010;20(3):185–91.PubMedGoogle Scholar
  136. 136.
    Malan L, Schutte AE, Malan NT, et al. Specific coping strategies of Africans during urbanization: comparing cardiovascular responses and perception of health data. Biol Psychol. 2006;72(3):305–10.PubMedGoogle Scholar
  137. 137.
    Reid JL, Morton DJ, Wingard DL, Garrett MD, von Muhlen D, Slymen D. Obesity and other cardiovascular disease risk factors and their association with osteoarthritis in Southern California American Indians, 2002–2006. Ethn Dis. 2010;20(4):416–22.PubMedGoogle Scholar
  138. 138.
    Heard E, Whitfield KE, Edwards CL, Bruce MA, Beech BM. Mediating effects of social support on the relationship among perceived stress, depression, and hypertension in African Americans. J Natl Med Assoc. 2011;103(2):116–22.PubMedGoogle Scholar
  139. 139.
    Mashele N, Van Rooyen JM, Malan L, Potgieter JC. Cardiovascular function and psychological distress in urbanised black South Africans: the SABPA study. Cardiovasc J Afr. 2010;21(4):206–11.PubMedGoogle Scholar
  140. 140.
    Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18–209.PubMedGoogle Scholar
  141. 141.
    Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation. 2002;105:2595–9.PubMedGoogle Scholar
  142. 142.
    Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factors. Circulation. 2004;109:II2–110.PubMedGoogle Scholar
  143. 143.
    Libby P, Ridker PM. Novel inflammatory markers of coronary risk. Theory versus practice. Circulation. 1999;100:1148–50.PubMedGoogle Scholar
  144. 144.
    Amer MS, Elawam AE, Khater MS, Omar OH, Mabrouk RA, Taha HM. Association of high-sensitivity C-reactive protein with carotid artery intima-media thickness in hypertensive older adults. J Am Soc Hypertens. 2011;5(5):395–400.PubMedGoogle Scholar
  145. 145.
    Little PJ, Chait A, Bobik A. Cellular and cytokine-based inflammatory processes as novel therapeutic targets for the prevention and treatment of atherosclerosis. Pharmacol Ther. 2011;131(3):255–68.PubMedGoogle Scholar
  146. 146.
    Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and risks of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–9.PubMedGoogle Scholar
  147. 147.
    Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007–11.PubMedGoogle Scholar
  148. 148.
    Pasceri P, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102: 2165–8.PubMedGoogle Scholar
  149. 149.
    Sakkinen P, Abbott RD, Curb JD, et al. C-reactive protein and myocardial infarction. J Clin Epidemiol. 2002;55:445–51.PubMedGoogle Scholar
  150. 150.
    Willerson JT. Systemic and local inflammation in patients with unstable atherosclerotic plaques. Prog Cardiovasc Dis. 2002;44:469–78.PubMedGoogle Scholar
  151. 151.
    Frasure-Smith N, Lespérance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA. 1993;270(15):1819–25.PubMedGoogle Scholar
  152. 152.
    Welin C, Lappas G, Wilhelmsen L. Independent importance of psychosocial factors for prognosis after myocardial infarction. J Intern Med. 2000;247(6):629–39.PubMedGoogle Scholar
  153. 153.
    Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med. 2004;66(6):802–13.PubMedGoogle Scholar
  154. 154.
    Rugulies R. Depression as a predictor for coronary heart disease. a review and meta-analysis. Am J Prev Med. 2002;23(1):51–61.PubMedGoogle Scholar
  155. 155.
    Appels A, Bär FW, Bär J, Bruggeman C, de Baets M. Inflammation, depressive symptomtology, and coronary artery disease. Psychosom Med. 2000;62(5):601–5.PubMedGoogle Scholar
  156. 156.
    Norman GJ, Zhang N, Morris JS, Karelina K, Berntson GG, DeVries AC. Social interaction modulates autonomic, inflammatory, and depressive-like responses to cardiac arrest and cardiopulmonary resuscitation. Proc Natl Acad Sci U S A. 2010;107(37):16342–7.PubMedGoogle Scholar
  157. 157.
    Thornton LM, Andersen BL, Schuler TA, Carson 3rd WE. A psychological intervention reduces inflammatory markers by alleviating depressive symptoms: secondary analysis of a randomized controlled trial. Psychosom Med. 2009;71(7):715–24.PubMedGoogle Scholar
  158. 158.
    Doering LV, Cross R, Vredevoe D, Martinez-Maza O, Cowan MJ. Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Altern Ther Health Med. 2007;13(3):18–21.PubMedGoogle Scholar
  159. 159.
    Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH, Nichols CD. Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency. J Pharmacol Exp Ther. 2008;327(2):316–23.PubMedGoogle Scholar
  160. 160.
    Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl). 2003;170(4):429–33.Google Scholar
  161. 161.
    Basterzi AD, Aydemir C, Kisa C, et al. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol. 2005;20(7):473–6.PubMedGoogle Scholar
  162. 162.
    Leo R, Di Lorenzo G, Tesauro M, et al. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J Clin Psychiatry. 2006;67(11):1760–6.PubMedGoogle Scholar
  163. 163.
    Kubera M, Maes M, Kenis G, Kim YK, Lasoń W. Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6. Psychiatry Res. 2005; 134(3):251–8.PubMedGoogle Scholar
  164. 164.
    Smedley BD, Stith AY, Nelson AR. Unequal treatment: confronting racial and ethnic disparities in health care. Washington, DC: The National Academies Press; 2002.Google Scholar
  165. 165.
    Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54(2):78–93.PubMedGoogle Scholar
  166. 166.
    Roberts CB, Vines AI, Kaufman JS, James SA. Cross-sectional association between perceived discrimination and hypertension in African-American men and women: the pitt county study. Am J Epidemiol. 2008;167:624–32.PubMedGoogle Scholar
  167. 167.
    Lewis TT, Barnes LL, Bienias JL, Lackland DT, Evans DA, Mendes de Leon CF. Perceived discrimination and blood pressure in older African American and White adults. J Gerontol A Biol Sci Med Sci. 2009;64A:1002–8.Google Scholar
  168. 168.
    Lewis TT, Aiello AE, Leurgans S, Kelly J, Barnes LL. Self-reported experiences of everyday discrimination are associated with elevated C-reactive protein levels in older African-American adults. Brain Behav Immun. 2010;24(3):438–43.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  1. 1.Department of Clinical PsychologyCalifornia School of Professional Psychology at Alliant International University—Los AngelesAlhambraUSA

Personalised recommendations